Laboratorios Farmacéuticos Rovi has expanded the presence of its enoxaparin in Europe, after launching a rival to Sanofi’s Lovenox under its own name in Spain and introducing its Crusia version in France via a partnership with Biogaran.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?